Estimation of the treatment effect in the presence of non-compliance and missing data

Statistics in Medicine

Volumn 33, Issue 2, 2014, Pages 193-208

  Leuchs, Ann Kristin ^a   Zinserling, Jörg ^a   Schlosser Weber, Gabriele ^a   Berres, Manfred ^b   Neuhäuser, Markus ^b   Benda, Norbert ^a  

^a Federal Institute for Drugs and Medical Devices BfArM   (Germany)

^b UNIVERSITY OF APPLIED SCIENCES KOBLENZ   (Germany)

Author keywords

Effectiveness; Missing data; Mixed models; Non compliance; Retrieved data

Indexed keywords

ARTICLE; CLINICAL OBSERVATION; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); DEPRESSION; DRUG DOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; LINEAR MIXED MODEL; LONGITUDINAL STUDY; PATIENT COMPLIANCE; STATISTICAL MODEL; THERAPY EFFECT; TREATMENT OUTCOME;

EFFECTIVENESS; MISSING DATA; MIXED MODELS; NON-COMPLIANCE; RETRIEVED DATA;

CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DEPRESSION; HUMANS; LONGITUDINAL STUDIES; PATIENT COMPLIANCE;

EID: 84890173007     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5924     Document Type: Article

References (38)

1. European Medicines Agency. EMA/CPMP/EWP/1776/99 Rev. 1-Guideline on missing data in confirmatory clinical trials, June 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/09/WC500096793.pdf.
2. Pocock SJ, Abdalla M. The hope and the hazards of using compliance data in randomized controlled trials. Statistics in Medicine 1998; 17:303-17.
3. Tillmann HC, Sharpe N, Sponer G, Wehling M. Does intention-to-treat analysis answer all questions in long-term mortality trials? Considerations on the basis of the ANZ trial. International Journal of Clinical Pharmacology and Therapeutics 2001; 39:205-12.
4. Little R, Yau L. Intention-to-treat analysis for longitudinal studies with drop-outs. Biometrics 1996; 52:1324-33.
5. Cuzick J, Edwards R, Segnan N. Adjusting for non-compliance and contamination in randomized clinical trials. Statistics in Medicine 1997; 16:1017-29.
6. Sommer A, Zeger SL. On estimating efficacy from clinical trials. Statistics in Medicine 1991; 10:45-52.
7. Elfron B, Feldman D. Compliance as an explanatory variable in clinical trials. Journal of the American Statistical Association 1991; 86:9-17.
8. Armijo-Olivo S, Warren S, Magee D. Intention-to-treat analysis, compliance, drop-outs and how to deal with missing data in clinical research: a review. Physical Therapy Reviews 2009; 14:36-49.
9. Mazumdar S, Houck PR, Liua KS, Mulsant BH, Pollock BG, Dew MA, Reynolds III CF. Intent-to-treat analysis for clinical trials: use of data collected after termination of treatment protocol. Journal of Psychiatric Research 2002; 36:153-164.
10. Prakash A, Risser RC, Mallinckrodt CH. The impact of analytic method on interpretation of outcomes in longitudinal clinical trials. International Journal of Clinical Practice 2008; 62:1147-58.
11. Little RJA, Rubin DB. Statistical Analysis with Missing Data. John Wiley & Sons: New York, 1987.
12. Hogan JW, Laird NM. Intention-to-treat analyses for incomplete repeated measures data. Biometrics 1996; 52:1002-17.
13. Mulsant BH, Pollock BG, Nebes RD, Miller MD, Little JT, Stack J, Houck PR, Bensasi S, Mazumdar S, Reynolds III CF. A double-blind randomized comparison of nortriptyline and paroxetine in the treatment of late-life depression: 6-week outcome. Journal of Clinical Psychiatry 1999; 60:16-20.
14. Mulsant BH, Pollock BG, Nebes RD, Miller MD, Sweet RA, Mazumdar S, Reynolds III CF. A twelve-week double-blind, randomized comparison of nortriptyline and paroxetine in older depressed inpatients and outpatients. American Journal of Geriatric Psychiatry 2001; 9:406-14.
15. White IB, Bamias C, Hardy P, Pocock S, Warner J. Randomized clinical trials with added rescue medication: some approaches to their analysis and interpretation. Statistics in Medicine 2001; 20:2995-3008.
16. Shaffer ML, Chinchilli VM. Including multiple imputation in a sensitivity analysis for clinical trials with treatment failures. Contemporary Clinical Trials 2006; 28:130-37.
17. Molenberghs G, Kenward MG. Missing Data in Clinical Studies. John Wiley & Sons: New York, 2007.
18. Elashoff RM, Li G, Li N. An approach to joint analysis of longitudinal measurements and competing risks failure time data. Statistics in Medicine 2007; 26:2813-35.
19. Elashoff RM, Li G, Li N. A joint model for longitudinal measurements and survival data in the presence of multiple failure types. Biometrics 2008; 64:762-71.
20. Kleinman KP, Ibrahim JG, Laird NM. A Bayesian framework for intent-to-treat analysis with missing data. Biometrics 1998; 54:265-78.
21. Naumova EN, Must A, Laird NM. Tutorial in biostatistics: evaluating the impact of critical periods in longitudinal studies of growth using piecewise mixed effect models. International Journal of Epidemiology 2001; 30:1332-41.
22. Houck PR, Mazumdar S, Koru-Sengul T, Tang G, Mulsant BH, Pollock BG, Reynolds III CF. Estimating treatment effects from longitudinal clinical trial data with missing values: comparative analyses using different methods. Psychiatry Research 2004; 129:209-15.
23. Fitzmaurice GM, Laird NM, Shneyer L. An alternative parameterization of the general linear mixture model for longitudinal data with non-ignorable drop-outs. Statistics in Medicine 2001; 20:1009-21.
24. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry 1960; 23:56-62.
25. European Medicines Agency. EMA/CHMP/185423/2010, Rev 2 previously (CPMP/EWP/518/97, Rev. 1)-Guideline on clinical investigation of medicinal products in the treatment of depression, June 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC500143770.pdf.
26. Mallinckrodt CH, Sanger TM, Dube S, DeBrota DJ, Molenberghs G, Carroll RJ, Potter WZ, Tollefson GD. Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biological Psychiatry 2003; 53:754-60.
27. Mallinckrodt CH, Clark WS, David SR. Type 1 error rates from mixed effects model repeated measures versus fixed effects ANOVA with missing values imputed via last observation carried forward. Drug Information Journal 2001; 35:1215-25.
28. Lavori PW. Clinical trials in psychiatry: should protocol deviation censor patient data. Neuropsychopharmacology 1992; 6:39-48.
29. Gibbons RD, Hedeker D, Elkin I, Waternaux C, Kraemer HC, Greenhouse JB, Shea T, Imber SD, Sotsky SM, Watkins JT. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Archives of General Psychiatry 1993; 50:739-50.
30. Mallinckrodt CH, Lane PW, Schnell D, Peng Y, Mancuso JP. Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials. Drug Information Journal 2008; 42:303-319.
31. Benda N, Branson M, Maurer W, Friede T. Aspects of modernizing drug development using clinical scenario planning and evaluation. Drug Information Journal 2010; 44:297-315.
32. Holland PW. Statistics and causal inference. Journal of the American Statistical Association 1968; 81:945-60.
33. Panel on Handling Missing Data in Clinical Trials and Committee on National Statistics and Division of Behavioral and Social Sciences and Education and National Research Council. The Prevention and Treatment of Missing Data in Clinical Trials. National Academies Press: Washington, D.C., 2010.
34. Mallinckrodt C. Preventing and Treating Missing Data in Longitudinal Clinical Trials: A Practical Guide, Practical Guides to Biostatistics and Epidemiology. Cambridge University Press: New York, 2013.
35. Pinheiro JC, Bates DM. Mixed-Effects Models in S and S-PLUS. Springer: New York, 2000.
36. Little RJA. Pattern-mixture models for multivariate incomplete data. Journal of the American Statistical Association 1993; 88:125-34.
37. Kornstein SG, Wohlreich MM, Mallinckrodt CH, Watkin JG, Steward DE. Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized double-blind, placebo-controlled trials. Journal of Clinical Psychiatry 2006; 67:761-70.
38. Bailey RK, Mallinckrodt CH, Wohlreich MM, Watkin JG, Plewes JM. Duloxetine in the treatment of major depressive disorder: comparison of safety and efficacy. Journal of the National Medical Association 2006; 98:437-47.